



Para más información:
Relación con Inversores (Tel: +34 91 244 44 22)
Marta Campos Martínez mcampos@rovi.es

ROVI announces an agreement with Biogaran for the marketing of its enoxaparin biosimilar in France

Madrid, 20 September, 2018 – Laboratorios Farmacéuticos Rovi, S.A. (ROVI:SM) announces that it has signed an agreement with Biogaran SAS, the leading French pharmaceutical company in biosimilar generic medicines and a subsidiary of Servier laboratories, for the semi-exclusive marketing of its enoxaparin biosimilar in France.

Enoxaparin is an anticoagulant medicine belonging to the low-molecular-weight heparin group. It is used to treat and prevent deep vein thrombosis and pulmonary embolism. As of 30 June, 2018, ROVI had obtained authorization for the marketing of its enoxaparin biosimilar from the competent national authorities in 21 European countries and direct marketing had commenced in Germany, the United Kingdom, Italy and Spain. ROVI has direct presence through international subsidiaries in top European enoxaparin markets as Germany, The United Kingdom, France and Italy.

Juan López-Belmonte Encina, ROVI's Chief Executive Officer, said, "We are very excited to announce our recent agreement with Biogaran, the leading hospital player in biosimilars in the French market and a leading generics company in the French retail market, which are one of the most important enoxaparin markets in Europe. Leveraging on the strong local presence of Biogaran, hospital specialists and patients in France will have access to our enoxaparin biosimilar. In this new phase, together with Biogaran, we hope to expand ROVI's international footprint and become a leader in the low-molecular-weight heparin field."

About ROVI

ROVI is a pan-European pharmaceutical company specializing and engaging in the research, development, contract manufacturing and marketing of small molecules and biological specialties. The company, in a continuous international expansion process, has subsidiaries in Portugal, Germany, the United Kingdom, Italy and France and has a diversified marketing portfolio of more than 40 products, among which its flagship product, Bemiparin, already marketed in 56 countries all over the world, should be highlighted. Likewise, in 2017, ROVI commenced the marketing of its enoxaparin biosimilar, developed in-house, in Europe. ROVI continues to develop the ISM® Platform technology, a leading-edge line of research in the field of prolonged drug release with proven advantages. For more information, please visit www.rovi.es

About Biogaran

Biogaran is a French pharmaceutical company specialized in generics and biosimilars. Founded in 1996, it has become the French leader in generics in retail and of biosimilars at hospital. It currently distributes 270 million boxes per annum and, in only a few years, it has become the third laboratory in France in terms of the number of medicines delivered to patients. Biogaran is present in Brazil through the company Pharlab. It is a full subsidiary of Servier